Evidence map›Paper›PMID 27887868›Full record

ArticleJournal of molecular biology2017

Reassessing APOBEC3G Inhibition by HIV-1 Vif-Derived Peptides.

Christopher M Richards, Ming Li, Angela L Perkins, Anurag Rathore, Daniel A Harki, Reuben S Harris

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christopher M RichardsDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street S.E., Minneapolis, MN 55455, USA; Institute for Molecular Virology, University of Minnesota, 515 Delaware Street S.E., Minneapolis, MN 55455, USA.
Ming LiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street S.E., Minneapolis, MN 55455, USA; Institute for Molecular Virology, University of Minnesota, 515 Delaware Street S.E., Minneapolis, MN 55455, USA.
Angela L PerkinsDepartment of Medicinal Chemistry, University of Minnesota, 2231 6th St. S.E., Minneapolis, MN 55455, USA.
Anurag RathoreDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street S.E., Minneapolis, MN 55455, USA.
Daniel A HarkiDepartment of Medicinal Chemistry, University of Minnesota, 2231 6th St. S.E., Minneapolis, MN 55455, USA.
Reuben S HarrisDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street S.E., Minneapolis, MN 55455, USA; Institute for Molecular Virology, University of Minnesota, 515 Delaware Street S.E., Minneapolis, MN 55455, USA; Howard Hughes Medical Institute, University of Minnesota, 2231 6th St. S.E., Minneapolis, MN 55455, USA. Electronic address: rsh@umn.edu.

Funding

Structural Characterization of APOBECS's Atomic interactionsP01GM091743 · NIGMS · UNIVERSITY OF MINNESOTA · PI KOTLER, MOSHE · 2011 to 2015
$10.1M
APOBEC3 Proteins in HIV RestrictionR37AI064046 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HARRIS, REUBEN S · 2015 to 2024
$4.2M
Minnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2M
APOBEC3 STRUCTURAL STUDIESR01GM118000 · NIGMS · UNIVERSITY OF MINNESOTA · PI AIHARA, HIDEKI, HARRIS, REUBEN S · 2016 to 2019
$2.2M
Chemical Interrogation of Human DNA Cytosine DeaminasesR01GM110129 · NIGMS · UNIVERSITY OF MINNESOTA · PI HARKI, DANIEL A · 2015 to 2019
$1.8M
Howard Hughes Medical InstituteNIAID NIH HHS R37 AI064046NIAID NIH HHS T32 AI083196NIGMS NIH HHS P01 GM091743NIGMS NIH HHS R01 GM110129NIGMS NIH HHS R01 GM118000
6 · The paper itself

Abstract

The human APOBEC3G (A3G) enzyme restricts HIV-1 in the absence of the viral accessory protein viral infectivity factor (Vif) by deaminating viral cDNA cytosines to uracils. These uracil lesions base-pair with adenines during the completion of reverse transcription and result in A3G signature G-to-A mutations in the viral genome. Vif protects HIV-1 from A3G-mediated restriction by forming an E3-ubiquitin ligase complex to polyubiquitinate A3G and trigger its degradation. Prior studies indicated that Vif may also directly block the enzymatic activity of A3G and, provocatively, that Vif-derived peptides, Vif 25-39 and Vif 105-119, are similarly inhibitory. Here, we show that Vif 25-39 does not inhibit A3G enzymatic activity and that the inhibitory effect of Vif 105-119 and that of a shorter derivative Vif 107-115, although recapitulated, are non-specific. We also elaborate a simple method for assaying DNA cytosine deaminase activity that eliminates potential polymerase chain reaction-induced biases. Our results show that these Vif-derived peptides are unlikely to be useful as tools to study A3G function or as leads for the development of future therapeutics.

Indexed as

APOBEC-3G DeaminaseEnzyme InhibitorsPeptidesvif Gene Products, Human Immunodeficiency VirusAPOBEC-3G DeaminaseAPOBEC3G protein, humanEnzyme InhibitorsPeptidesvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1DNA cytosine deaminationEvolvabilityHIV-1MutationVif-derived peptides

Identifiers

PMID27887868
PMCPMC5186364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.